Curated News
By: NewsRamp Editorial Staff
March 18, 2026
VolitionRx Achieves 99% Purity Breakthrough in Cancer DNA Detection
TLDR
- VolitionRx's breakthrough liquid biopsy technology offers a competitive edge with over 99% purity in cancer DNA detection, targeting a $36 billion market for early cancer detection.
- VolitionRx's Capture-Seq platform isolates circulating tumor DNA with over 99% purity by distinguishing it from healthy cell-free DNA, validated with no false positives in initial studies.
- This advancement in liquid biopsy technology could improve cancer detection and monitoring, potentially saving lives and enhancing patient quality of life through earlier intervention.
- VolitionRx achieved a breakthrough in liquid biopsy by isolating cancer DNA with over 99% purity, a significant step toward non-invasive multi-cancer early detection.
Impact - Why it Matters
This breakthrough represents a potential paradigm shift in cancer diagnostics that could save countless lives through earlier detection. Liquid biopsy technology has long promised a less invasive alternative to traditional tissue biopsies, but the challenge of distinguishing cancer DNA from normal DNA in blood samples has limited its accuracy and clinical utility. VolitionRx's achievement of over 99% purity addresses this fundamental limitation, potentially enabling reliable blood tests for early cancer detection when treatment is most effective. For patients, this could mean earlier diagnosis, better treatment outcomes, and reduced need for invasive procedures. For healthcare systems, it offers the possibility of more accessible, cost-effective screening that could dramatically improve cancer survival rates globally. The technology's applications in both early detection and monitoring treatment response make it particularly valuable in the ongoing fight against cancer, which remains a leading cause of death worldwide.
Summary
VolitionRx (NYSE American: VNRX) has announced a major breakthrough in liquid biopsy technology, achieving over 99% purity in isolating circulating tumor-derived DNA using its proprietary Capture-Seq™ platform. This advancement overcomes a critical challenge in cancer diagnostics—distinguishing cancer DNA from healthy cell-free DNA in blood samples—with the company reporting strong early validation results including no false positives and successful detection across initial study cohorts. The technology represents a novel biomarker approach that could revolutionize early cancer detection and monitoring.
The breakthrough has significant commercial potential, with applications in multi-cancer early detection and minimal residual disease monitoring representing a combined total addressable market of approximately $36 billion. Volition is currently in active discussions with global diagnostic and liquid biopsy companies to accelerate development and commercialization of the platform. The company's research and development activities are centered in Belgium, with additional facilities in the U.S. and London, positioning it as a multi-national leader in epigenetic science.
For investors and stakeholders interested in tracking the company's progress, detailed market research and analysis is available through the InvestorBrandNetwork platform, which provides comprehensive financial data and news coverage. The full press release can be accessed at https://ibn.fm/1ZqGi, offering complete details about this technological advancement. Volition's broader mission focuses on saving lives through earlier detection of life-altering diseases, with their website at https://volition.com/ providing additional information about their research initiatives and corporate vision.
This news was distributed through InvestorWire, a specialized communications platform within the IBN (InvestorBrandNetwork) portfolio that provides advanced wire-grade press release syndication and corporate communications solutions. The Dynamic Brand Portfolio offers comprehensive distribution services including article syndication to over 5,000 outlets, enhanced press release features, and social media distribution to millions of followers, ensuring maximum visibility for important corporate announcements like this breakthrough in cancer detection technology.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, VolitionRx Achieves 99% Purity Breakthrough in Cancer DNA Detection
